We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.09 | 0.30% | 29.91 | 29.94 | 29.98 | 29.99 | 29.53 | 29.80 | 3,494,088 | 19:42:51 |
By Pierre Bertrand
Roche Holding AG said Wednesday that its monkeypox virus test has received emergency use authorization by the U.S. Food and Drug Administration.
Cobas MPXV is a real-time PCR test which detects the presence of monkeypox virus DNA from lesion swabs, the Swiss medical company said.
The test targets two different regions of the virus' genome, both of which are less prone to mutation, ensuring the test will continue to identify cases of the virus even in the event of a mutation in one of the test's target zones, Roche said.
The test received emergency use authorization by the U.S. regulator after evaluating results from samples taken from patients, rather than from a laboratory, Roche said.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
November 16, 2022 01:39 ET (06:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions